LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.

C4XD

C4x Discovery Holdings Plc

16.325
0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 16.325 0.00 12:00:03
Bid Price Offer Price High Price Low Price Open Price
15.55 16.95
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 2.70 -8.16 -3.60 - 41.16
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 16.325 GBX

C4x Discovery (C4XD) Latest News

C4x Discovery (C4XD) Discussions and Chat

C4x Discovery Forums and Chat

Date Time Title Posts
01/6/202307:39C4X Discovery Holdings plc2,854

Add a New Thread

C4x Discovery (C4XD) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

C4x Discovery (C4XD) Top Chat Posts

Top Posts
Posted at 26/4/2023 09:40 by copandrobber
This is such a good buy at this price! If anyone ventures onto this board, have a look at their half year results and then enjoy buying a great company that is totally overlooked and undervalued! This will get taken out or taken private at a significantly higher price than it is today!! You heard it here first!!
Posted at 19/1/2023 14:10 by davemac3
that RNS looks like an attempt to shore up the share price. We need some milestone payments from the partnered projects or I can see another fund raise in the not too distant future.
Posted at 19/12/2022 19:15 by noirua
Annual report and accounts 2022
C4X Discovery Holdings plc Annual report and accounts 2022
Https://www.c4xdiscovery.com/wp-content/uploads/2022/12/C4XD-2022-Annual-Report-Final.pdf
Harnessing the Power of Drug Discovery

C4XD signs exclusive global licence worth up to $402 million with AstraZeneca for the development and commercialisation of NRF2 Activator programme
Contact
November 28, 2022 Press Releases
Https://www.c4xdiscovery.com/c4xd-signs-exclusive-global-licence-worth-up-to-402-million1-with-astrazeneca-for-the-development-and-commercialisation-of-nrf2-activator-programme/

Posted at 05/12/2022 07:05 by alloa2003
There appears to be a seller in the market at the moment - a hangover from the AZ deal which seemed to go down well but then the price retraced.

I am surprised more people are not following this stock as similar stocks in the US are trading on multiples of the C4XD market cap. Will be interesting to see what the full year results show as on the whole it has been a decent year for the company. Hopefully we will get some news on the pipeline.

Posted at 02/12/2022 13:41 by alloa2003
I have been in and out of this over the years and always kept a close eye on the company. You are correct, they are getting bundled in with the speculative pharma rubbish. The AZ deal has been in negotiations for ages and people are misisng the point, the $16m payment pre-clinical trials (with $2m up front) is AZ paying C4XD to do the work themselves, madness the market has missed this. This is C4XD's biggest pre-clinical trial payment to date.

As far as funding, they had cash, then the £5m placing and now the $2m payment with more to follow. I think I read they have enought cash for at least 2 years.

As soon as one drug goes to market this will become a cash cow. Many people are also missing the point with the payments. As well as stage payment due when a compound gets to market, C4XD will get royalties forever which is where the big bucks come in. So overlooked it is unreal. Just my view, DYOR

Posted at 30/11/2022 18:27 by ivor hunch
I am a firm believer in the potential of this company. Marketcap is £57 million but there is over $1 billion deals in the pipeline, and more to come. The only reason c4xd is not flying is the market's horror of any speculative share. This week c4xd announced a mega deal with AstraZeneca. A few years ago, pre-Covid, the news would have sent the shares soaring. Instead they rose 35% in the morning then continued to fall to below this summer's issue price of 25p. It's madness really, especially if the 3 deals proceed as planned - Indivior, Sanofi and AstraZeneca - all major players.
Someone tell me what I'm missing please...

Posted at 29/11/2022 08:00 by alloa2003
Been in and out of this one over the years and looking to get back in with a large chunk if other investments come through. The share price move is madness - this is still a big deal and there is at least one huge one still to come in the short term. The up front payment is substantial and lets not forget institutions approached the company about the recent fund raising at 25p. When one or more treatments hits the market, this will release huge milestone payments and - as some people seem to forget - a royalty forever.
Posted at 28/11/2022 07:38 by t0pgrader
Company A in the fund's list of three is presumably C4XDhttps://clsc-docs.s3-eu-west-2.amazonaws.com/PEF-CLSC-Prospectus-Final.pdf
Posted at 29/6/2022 11:23 by alloa2003
What is happening here? Looks like the company is slowly dying but behind the scenes negotiations continue on licence deals. I hope funding doesnt become an issue before they sign a deal - looking that way with the share price.
Posted at 25/8/2020 22:20 by the stigologist
Perfectly normal for Deputy Chair of UK Vaccine Taskforce to speak to Bill Gates

Interestingly Bill Gates is one of biggest investors in Schrodinger (SDGR) Mkt Cap $5bn

Schrodinger is the nearest equivalent to C4XD

IF C4XD share price doesn't go up soon I can see a US Company snapping them up for 100p+

The Indivior deal alone at $294m makes C4XD cheap at 100p (c.£130m Mkt Cap)

Clive today told us the NRF2/IL17/a4B7 projects have similar potential

C4x Discovery share price data is direct from the London Stock Exchange
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

V: D: 20230602 15:50:06